300966 共同药业
已收盘 11-22 15:00:00
资讯
新帖
简况
共同药业(300966)11月4日主力资金净卖出747.50万元
证券之星 · 11-05
共同药业(300966)11月4日主力资金净卖出747.50万元
共同药业(300966)11月1日主力资金净买入222.02万元
证券之星 · 11-04
共同药业(300966)11月1日主力资金净买入222.02万元
共同药业(300966)2024年三季报简析:净利润减162.16%
证券之星 · 10-25
共同药业(300966)2024年三季报简析:净利润减162.16%
图解共同药业三季报:第三季度单季净利润同比减270.23%
证券之星 · 10-23
图解共同药业三季报:第三季度单季净利润同比减270.23%
共同药业(300966.SZ)发布前三季度业绩,净亏损1416.22万元
智通财经 · 10-23
共同药业(300966.SZ)发布前三季度业绩,净亏损1416.22万元
共同药业控股股东抛减持计划:业绩连年下滑毛利率低于可比企业 存货周转率创新低仍在扩产
新浪证券 · 10-16
共同药业控股股东抛减持计划:业绩连年下滑毛利率低于可比企业 存货周转率创新低仍在扩产
共同药业(300966.SZ)股东丹创投、张欣拟合计减持不超3%股份
智通财经网 · 09-27
共同药业(300966.SZ)股东丹创投、张欣拟合计减持不超3%股份
共同药业最新公告:控股股东、实际控制人的一致行动人拟减持不超过3%
证券之星 · 09-27
共同药业最新公告:控股股东、实际控制人的一致行动人拟减持不超过3%
共同药业:控股股东、实际控制人的一致行动人丹创投、张欣计划减持公司股份不超过3,458,367股,即减持比例不超过公司当前总股本的3%。
美港电讯 · 09-27
共同药业:控股股东、实际控制人的一致行动人丹创投、张欣计划减持公司股份不超过3,458,367股,即减持比例不超过公司当前总股本的3%。
共同药业最新公告:全资子公司共同生物收到3080万元政府补助
证券之星 · 09-20
共同药业最新公告:全资子公司共同生物收到3080万元政府补助
共同药业:关于公司项目的信息,具体请以定期报告或临时性公告披露的信息为准
证券之星 · 09-06
共同药业:关于公司项目的信息,具体请以定期报告或临时性公告披露的信息为准
太平洋:给予共同药业增持评级,目标价位20.0元
证券之星 · 08-30
太平洋:给予共同药业增持评级,目标价位20.0元
共同药业(300966)8月29日主力资金净买入70.44万元
证券之星 · 08-30
共同药业(300966)8月29日主力资金净买入70.44万元
共同药业(300966)2024年中报简析:净利润减129.3%,三费占比上升明显
证券之星 · 08-29
共同药业(300966)2024年中报简析:净利润减129.3%,三费占比上升明显
共同药业(300966)8月19日主力资金净卖出423.06万元
证券之星 · 08-20
共同药业(300966)8月19日主力资金净卖出423.06万元
共同药业(300966)8月7日主力资金净卖出101.58万元
证券之星 · 08-08
共同药业(300966)8月7日主力资金净卖出101.58万元
华海药业:湖北华海共同药业有限公司尚处于建设阶段
每日经济新闻 · 07-31
华海药业:湖北华海共同药业有限公司尚处于建设阶段
共同药业获得实用新型专利授权:“一种可快速清洁的萃取罐”
证券之星 · 07-06
共同药业获得实用新型专利授权:“一种可快速清洁的萃取罐”
共同药业最新公告:截至7月5日累计新增借款2.81亿元 超过上年末净资产20%
证券之星 · 07-05
共同药业最新公告:截至7月5日累计新增借款2.81亿元 超过上年末净资产20%
共同药业(300966)7月1日主力资金净买入699.10万元
证券之星 · 07-02
共同药业(300966)7月1日主力资金净买入699.10万元
加载更多
公司概况
公司名称:
湖北共同药业股份有限公司
所属行业:
医药制造业
上市日期:
2021-04-09
主营业务:
湖北共同药业股份有限公司的主营业务为甾体药物起始物料和中间体的研发、生产及销售,主要产品为甾体药物生产所需的起始物料和中间体。公司自成立以来专注于主营业务发展和科技创新,获得了各级政府及主管部门的认可和奖励。公司被认定为“湖北省植物甾醇工程技术研究中心”、“湖北省甾体药物及中间体工程研究中心”和“院士(专家)工作站”;并获得“省科技进步奖二等奖”、“科技型中小企业创新奖”和“发展工业经济优秀单位”等荣誉,凭借“利用植物甾醇发酵生产雄烯二酮新工艺”获得了中国生产力促进中心协会颁布的“中国好技术”称号。
发行价格:
8.24
{"stockData":{"symbol":"300966","market":"SZ","secType":"STK","nameCN":"共同药业","latestPrice":17.62,"timestamp":1732259001000,"preClose":18.72,"halted":0,"volume":2415900,"delay":0,"floatShares":75132200,"shares":114999999,"eps":-0.121,"marketStatus":"已收盘","marketStatusCode":5,"change":-1.1,"latestTime":"11-22 15:00:00","open":18.72,"high":18.8,"low":17.6,"amount":44033200,"amplitude":0.0641,"askPrice":17.65,"askSize":30,"bidPrice":17.62,"bidSize":78,"shortable":0,"etf":0,"ttmEps":-0.121,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"adjPreClose":18.72,"symbolType":"stock","openAndCloseTimeList":[[1732239000000,1732246200000],[1732251600000,1732258800000]],"highLimit":20.59,"lowLimit":16.85,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":115279306,"pbRate":2.56,"roa":"--","roe":"--","epsLYR":0.2,"committee":0.451264,"marketValue":2031000000,"floatMarketCap":1324000000,"peRate":-145.619835,"changeRate":-0.0588,"turnoverRate":0.0322,"status":1},"requestUrl":"/m/hq/s/300966","defaultTab":"news","newsList":[{"id":"2481599658","title":"共同药业(300966)11月4日主力资金净卖出747.50万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481599658","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481599658?lang=zh_cn&edition=full","pubTime":"2024-11-05 09:22","pubTimestamp":1730769724,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年11月4日收盘,共同药业报收于18.7元,下跌2.04%,换手率5.45%,成交量4.09万手,成交额7615.98万元。11月4日的资金流向数据方面,主力资金净流出747.5万元,占总成交额9.81%,游资资金净流入181.35万元,占总成交额2.38%,散户资金净流入566.15万元,占总成交额7.43%。近5日资金流向一览见下表:共同药业融资融券信息显示,融资方面,当日融资买入676.26万元,融资偿还653.19万元,融资净买入23.07万元,连续3日净买入累计542.12万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110500008143.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"gpt_icon":0},{"id":"2480317811","title":"共同药业(300966)11月1日主力资金净买入222.02万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480317811","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480317811?lang=zh_cn&edition=full","pubTime":"2024-11-04 09:18","pubTimestamp":1730683096,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年11月1日收盘,共同药业报收于19.09元,上涨1.06%,换手率9.18%,成交量6.9万手,成交额1.3亿元。11月1日的资金流向数据方面,主力资金净流入222.02万元,占总成交额1.7%,游资资金净流入40.54万元,占总成交额0.31%,散户资金净流出262.56万元,占总成交额2.02%。近5日资金流向一览见下表:共同药业融资融券信息显示,融资方面,当日融资买入1731.05万元,融资偿还1434.89万元,融资净买入296.16万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110400002427.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"gpt_icon":0},{"id":"2478697358","title":"共同药业(300966)2024年三季报简析:净利润减162.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478697358","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478697358?lang=zh_cn&edition=full","pubTime":"2024-10-25 06:09","pubTimestamp":1729807773,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期共同药业发布2024年三季报。根据财报显示,共同药业净利润减162.16%。截至本报告期末,公司营业总收入3.65亿元,同比下降5.1%,归母净利润-1416.22万元,同比下降162.16%。按单季度数据看,第三季度营业总收入1.32亿元,同比上升12.24%,第三季度归母净利润-904.36万元,同比下降270.23%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102500005356.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966"],"gpt_icon":0},{"id":"2477837045","title":"图解共同药业三季报:第三季度单季净利润同比减270.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477837045","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477837045?lang=zh_cn&edition=full","pubTime":"2024-10-23 16:47","pubTimestamp":1729673251,"startTime":"0","endTime":"0","summary":"证券之星消息,共同药业2024年三季报显示,公司主营收入3.65亿元,同比下降5.1%;归母净利润-1416.22万元,同比下降162.16%;扣非净利润-1477.05万元,同比下降190.91%;其中2024年第三季度,公司单季度主营收入1.32亿元,同比上升12.24%;单季度归母净利润-904.36万元,同比下降270.23%;单季度扣非净利润-984.36万元,同比下降399.98%;负债率61.76%,投资收益38.24万元,财务费用1347.09万元,毛利率14.23%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102300027183.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966"],"gpt_icon":0},{"id":"2477372645","title":"共同药业(300966.SZ)发布前三季度业绩,净亏损1416.22万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477372645","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477372645?lang=zh_cn&edition=full","pubTime":"2024-10-23 16:25","pubTimestamp":1729671947,"startTime":"0","endTime":"0","summary":"智通财经APP讯,共同药业(300966.SZ)发布2024年第三季度报告,公司前三季度营业收入3.65亿元,同比下降5.10%;归属于上市公司股东的净亏损1416.22万元;归属于上市公司股东的扣除非经常性损益的净亏损1477.05万元;基本每股亏损0.12元/股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1197980.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300966","BK0239"],"gpt_icon":0},{"id":"2475969881","title":"共同药业控股股东抛减持计划:业绩连年下滑毛利率低于可比企业 存货周转率创新低仍在扩产","url":"https://stock-news.laohu8.com/highlight/detail?id=2475969881","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475969881?lang=zh_cn&edition=full","pubTime":"2024-10-16 19:11","pubTimestamp":1729077060,"startTime":"0","endTime":"0","summary":" 近期A股市场持续上涨,引发了一波上市公司股东、高管减持潮。其中,共同药业、振德医疗、溢多利减持方为控股股东。在起始物料产品价格下滑,公司毛利率持续走低,2023年存货周转率创历史新低的背景下,新增产能能否被市场消化仍有待观察。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/observe/2024-10-16/doc-incstxuz6908136.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2024-10-16/doc-incstxuz6908136.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300966","BK0239"],"gpt_icon":0},{"id":"2470084701","title":"共同药业(300966.SZ)股东丹创投、张欣拟合计减持不超3%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2470084701","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470084701?lang=zh_cn&edition=full","pubTime":"2024-09-27 19:32","pubTimestamp":1727436773,"startTime":"0","endTime":"0","summary":"智通财经APP讯,共同药业(300966.SZ)公告,公司近日收到控股股东、实际控制人的一致行动人丹江口市共同创新投资合伙企业(有限合伙)(简称“丹创投”)、张欣出具的《关于股份减持计划的告知函》,丹创投、张欣计划以集中竞价交易方式或大宗交易方式减持公司股份不超过345.84万股(即减持比例不超过公司当前总股本的3%)。更多港股重磅资讯,下载智通财经app更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1188379.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["00410","BK1229","BK0239","BK1555","BK1258","300966"],"gpt_icon":0},{"id":"2470704394","title":"共同药业最新公告:控股股东、实际控制人的一致行动人拟减持不超过3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2470704394","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470704394?lang=zh_cn&edition=full","pubTime":"2024-09-27 19:30","pubTimestamp":1727436639,"startTime":"0","endTime":"0","summary":"共同药业公告,公司控股股东、实际控制人的一致行动人丹创投、张欣计划以集中竞价交易方式或大宗交易方式减持公司股份不超过345.84万股,即减持比例不超过公司当前总股本的3%。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092700034997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966","BK0239"],"gpt_icon":0},{"id":"2470701511","title":"共同药业:控股股东、实际控制人的一致行动人丹创投、张欣计划减持公司股份不超过3,458,367股,即减持比例不超过公司当前总股本的3%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2470701511","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470701511?lang=zh_cn&edition=full","pubTime":"2024-09-27 19:27","pubTimestamp":1727436430,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["300966","BK1555","BK0239","BK1229","BK1258","00410"],"gpt_icon":0},{"id":"2468561900","title":"共同药业最新公告:全资子公司共同生物收到3080万元政府补助","url":"https://stock-news.laohu8.com/highlight/detail?id=2468561900","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468561900?lang=zh_cn&edition=full","pubTime":"2024-09-20 16:50","pubTimestamp":1726822224,"startTime":"0","endTime":"0","summary":"共同药业公告,全资子公司共同生物近日收到与资产相关的政府补助资金3080万元,占公司2023年度经审计净资产的比例为3.23%。公司将与资产相关的政府补助确认为递延收益,在相关资产使用寿命内按照合理、系统的方法分期计入损益。具体会计处理以会计师事务所审计确认的结果为准。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092000023952.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"gpt_icon":0},{"id":"2465660109","title":"共同药业:关于公司项目的信息,具体请以定期报告或临时性公告披露的信息为准","url":"https://stock-news.laohu8.com/highlight/detail?id=2465660109","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2465660109?lang=zh_cn&edition=full","pubTime":"2024-09-06 19:03","pubTimestamp":1725620628,"startTime":"0","endTime":"0","summary":"证券之星消息,共同药业09月06日在投资者关系平台上答复投资者关心的问题。投资者:共同药业半年报未披露维生素D3项目进展的信息,能否做补充说明!","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090600033609.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"gpt_icon":0},{"id":"2463279082","title":"太平洋:给予共同药业增持评级,目标价位20.0元","url":"https://stock-news.laohu8.com/highlight/detail?id=2463279082","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463279082?lang=zh_cn&edition=full","pubTime":"2024-08-30 12:01","pubTimestamp":1724990503,"startTime":"0","endTime":"0","summary":"太平洋证券股份有限公司周豫,乔露阳近期对共同药业进行研究并发布了研究报告《Q2业绩略低于市场预期,下半年产能投放有望助力收入快速增长》,本报告对共同药业给出增持评级,认为其目标价位为20.00元,当前股价为15.0元,预期上涨幅度为33.33%。产能方面,截至2024年6月底,一期产品建设工程基本完工,并追加了二期产品生产线,不断丰富原料药生产线及产品。此外,部分产业链升级改造项目有望于2024H2顺利投产并实现收益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024083000018962.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601099","300966"],"gpt_icon":0},{"id":"2463244481","title":"共同药业(300966)8月29日主力资金净买入70.44万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2463244481","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463244481?lang=zh_cn&edition=full","pubTime":"2024-08-30 09:17","pubTimestamp":1724980677,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月29日收盘,共同药业报收于14.71元,上涨3.81%,换手率3.37%,成交量2.53万手,成交额3665.65万元。8月29日的资金流向数据方面,主力资金净流入70.44万元,占总成交额1.92%,游资资金净流出218.23万元,占总成交额5.95%,散户资金净流入147.79万元,占总成交额4.03%。融券方面,融券卖出0.0股,融券偿还0.0股,融券余量8100.0股,融券余额11.92万元。共同药业主营业务:专业从事甾体药物原料的研发、生产及销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024083000010235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"gpt_icon":0},{"id":"2463443016","title":"共同药业(300966)2024年中报简析:净利润减129.3%,三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2463443016","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463443016?lang=zh_cn&edition=full","pubTime":"2024-08-29 06:29","pubTimestamp":1724884157,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期共同药业发布2024年中报。截至本报告期末,公司营业总收入2.34亿元,同比下降12.69%,归母净利润-511.86万元,同比下降129.3%。本报告期共同药业三费占比上升明显,财务费用、销售费用和管理费用总和占总营收同比增幅达49.82%。去年的净利率为3.76%,算上全部成本后,公司产品或服务的附加值不高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082900007122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966"],"gpt_icon":0},{"id":"2460090926","title":"共同药业(300966)8月19日主力资金净卖出423.06万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2460090926","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460090926?lang=zh_cn&edition=full","pubTime":"2024-08-20 09:18","pubTimestamp":1724116713,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月19日收盘,共同药业报收于16.22元,下跌3.97%,换手率3.83%,成交量2.88万手,成交额4714.79万元。8月19日的资金流向数据方面,主力资金净流出423.06万元,占总成交额8.97%,游资资金净流入189.01万元,占总成交额4.01%,散户资金净流入234.05万元,占总成交额4.96%。融券方面,融券卖出0.0股,融券偿还0.0股,融券余量8100.0股,融券余额13.14万元。共同药业主营业务:专业从事甾体药物原料的研发、生产及销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082000006995.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"gpt_icon":0},{"id":"2457384771","title":"共同药业(300966)8月7日主力资金净卖出101.58万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2457384771","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457384771?lang=zh_cn&edition=full","pubTime":"2024-08-08 09:48","pubTimestamp":1723081734,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月7日收盘,共同药业报收于16.59元,下跌2.12%,换手率3.36%,成交量2.52万手,成交额4204.4万元。8月7日的资金流向数据方面,主力资金净流出101.58万元,占总成交额2.42%,游资资金净流出429.84万元,占总成交额10.22%,散户资金净流入531.41万元,占总成交额12.64%。融券方面,融券卖出0.0股,融券偿还0.0股,融券余量8100.0股,融券余额13.44万元。共同药业主营业务:专业从事甾体药物原料的研发、生产及销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080800014499.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"gpt_icon":0},{"id":"2455069259","title":"华海药业:湖北华海共同药业有限公司尚处于建设阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2455069259","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455069259?lang=zh_cn&edition=full","pubTime":"2024-07-31 16:43","pubTimestamp":1722415412,"startTime":"0","endTime":"0","summary":"每经AI快讯,有投资者在投资者互动平台提问:请问贵司华海共同经营情况到什么阶段?华海药业(600521.SH)7月31日在投资者互动平台表示,湖北华海共同药业有限公司尚处于建设阶段。(记者 毕陆名)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407311644059f0174d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407311644059f0174d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600521","BK0185","BK0239","BK0188","BK0201","BK0012","300966","BK0070","BK0028"],"gpt_icon":0},{"id":"2449219180","title":"共同药业获得实用新型专利授权:“一种可快速清洁的萃取罐”","url":"https://stock-news.laohu8.com/highlight/detail?id=2449219180","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449219180?lang=zh_cn&edition=full","pubTime":"2024-07-06 03:09","pubTimestamp":1720206544,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示共同药业新获得一项实用新型专利授权,专利名为“一种可快速清洁的萃取罐”,专利申请号为CN202322901689.2,授权日为2024年7月5日。结合公司2023年年报财务数据,2023年公司在研发方面投入了3809.89万元,同比减15.61%。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070600003514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"gpt_icon":0},{"id":"2449637022","title":"共同药业最新公告:截至7月5日累计新增借款2.81亿元 超过上年末净资产20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2449637022","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449637022?lang=zh_cn&edition=full","pubTime":"2024-07-05 19:09","pubTimestamp":1720177793,"startTime":"0","endTime":"0","summary":"共同药业公告,截至2024年7月5日,公司借款余额为7.62亿元(未经审计),较2023年末增加2.81亿元,2024年累计新增借款占2023年末净资产的27.45%。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070500041020.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300966","BK0239"],"gpt_icon":0},{"id":"2448973737","title":"共同药业(300966)7月1日主力资金净买入699.10万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448973737","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448973737?lang=zh_cn&edition=full","pubTime":"2024-07-02 09:14","pubTimestamp":1719882849,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月1日收盘,共同药业报收于17.09元,上涨4.59%,换手率7.57%,成交量5.43万手,成交额9161.56万元。7月1日的资金流向数据方面,主力资金净流入699.1万元,占总成交额7.63%,游资资金净流入956.88万元,占总成交额10.44%,散户资金净流出1655.98万元,占总成交额18.08%。近5日资金流向一览见下表:共同药业融资融券信息显示,融资方面,当日融资买入1192.05万元,融资偿还428.99万元,融资净买入763.07万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070200006440.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300966"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2021-04-09","address":"湖北省襄阳市宜城市小河镇高坑一组","stockEarnings":[{"period":"1week","weight":-0.0387},{"period":"1month","weight":-0.0542},{"period":"3month","weight":0.1802},{"period":"6month","weight":-0.1744},{"period":"1year","weight":-0.3098},{"period":"ytd","weight":-0.2322}],"companyName":"湖北共同药业股份有限公司","boardCode":"AI0027","perCapita":"5290股","boardName":"医药制造业","registeredCapital":"11527万元","compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0108},{"period":"3month","weight":0.1446},{"period":"6month","weight":0.0577},{"period":"1year","weight":0.0671},{"period":"ytd","weight":0.0982}],"survey":" 湖北共同药业股份有限公司的主营业务为甾体药物起始物料和中间体的研发、生产及销售,主要产品为甾体药物生产所需的起始物料和中间体。公司自成立以来专注于主营业务发展和科技创新,获得了各级政府及主管部门的认可和奖励。公司被认定为“湖北省植物甾醇工程技术研究中心”、“湖北省甾体药物及中间体工程研究中心”和“院士(专家)工作站”;并获得“省科技进步奖二等奖”、“科技型中小企业创新奖”和“发展工业经济优秀单位”等荣誉,凭借“利用植物甾醇发酵生产雄烯二酮新工艺”获得了中国生产力促进中心协会颁布的“中国好技术”称号。","serverTime":1732417003434,"listedPrice":8.24,"stockholders":"14201人(较上一季度减少7.27%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"共同药业(300966)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供共同药业(300966)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"共同药业,300966,共同药业股票,共同药业股票老虎,共同药业股票老虎国际,共同药业行情,共同药业股票行情,共同药业股价,共同药业股市,共同药业股票价格,共同药业股票交易,共同药业股票购买,共同药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"共同药业(300966)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供共同药业(300966)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}